Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

Michael L.H. Wang; W. K.Alfred Yung; Melanie E. Royce; Donald F. Schomer; Richard L. Theriault; Christine F. Wogan

doi:10.1097/00000421-200108000-00026

Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

Michael L.H. Wang, W. K.Alfred Yung, Melanie E. Royce, Donald F. Schomer, Richard L. Theriault, Christine F. Wogan

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.

Original language	English (US)
Pages (from-to)	421-424
Number of pages	4
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	24
Issue number	4
DOIs	https://doi.org/10.1097/00000421-200108000-00026
State	Published - 2001

Keywords

Brain metastasis
Breast cancer
Capecitabine

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-200108000-00026

Cite this

@article{1aaee905db5f4f00b5f3530cd2800470,

title = "Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer",

abstract = "We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.",

keywords = "Brain metastasis, Breast cancer, Capecitabine",

author = "Wang, {Michael L.H.} and Yung, {W. K.Alfred} and Royce, {Melanie E.} and Schomer, {Donald F.} and Theriault, {Richard L.} and Wogan, {Christine F.}",

year = "2001",

doi = "10.1097/00000421-200108000-00026",

language = "English (US)",

volume = "24",

pages = "421--424",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

AU - Wang, Michael L.H.

AU - Yung, W. K.Alfred

AU - Royce, Melanie E.

AU - Schomer, Donald F.

AU - Theriault, Richard L.

AU - Wogan, Christine F.

PY - 2001

Y1 - 2001

N2 - We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.

AB - We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.

KW - Brain metastasis

KW - Breast cancer

KW - Capecitabine

UR - http://www.scopus.com/inward/record.url?scp=0034903131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034903131&partnerID=8YFLogxK

U2 - 10.1097/00000421-200108000-00026

DO - 10.1097/00000421-200108000-00026

M3 - Article

C2 - 11474279

AN - SCOPUS:0034903131

SN - 0277-3732

VL - 24

SP - 421

EP - 424

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 4

ER -

Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this